Seven opioid analytes including codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone were detected in postmortem blood (n > 1000). Two milliliters of specimen was deproteinated with ~ 2.5 mL of methanol and derivatized with hydroxylamine before solid-phase extraction and derlvatization with BSTFA + 1% TMCS. Extracts were assayed by gas chromatography-electron impact-mass spectrometry utilizing selected ion mode. One-microliter aliquots were injected onto an HP-1MS capillary column (30 m x 0.25-mm i.d., 0.25 pm) with a helium linear velocity of 62 cm/s. Temperature programming began at 160~ (hold 0 min), then increased at rates of 35~ to 195~ 5~ to 240~ and 30~ to 300~ (hold 2 rain) resulting in a total run time of 14-min. Quantitative determinations were based on the ratios of the analyte peak areas to the corresponding deuterated analogues. Calibration curves were linear for the following concentrations: 10-500 ng/mL (6-AM), 100-2000 ng/mL (oxycodone), and 50-1000 ng/ml. (all other opioids). LOQs ranged from 5 ng/mL (6-AM) to 20 ng/mL (oxycodone). Between-run precision yielded CVs ranging from 2.79% to 5.34% (n = 12). These data suggest that methanolic deproteination and dual derivatization improve separation and simultaneous quantitation of seven opioid analytes in difficult matrices.
Introduction
Opioid abuse remains a major problem in North American society. Opioid prescriptions rose dramatically from 1990 to 1996 as reported by the Drug Enforcement Administration's (DEA) Automation of Reports and Consolidated Orders System * Author m whom correspondence should be addcessed, Office of the Chief MedlcaJ Examiner, 1001 Brinkhous Bullitt Building, CB#7580, Chapel Hill, NC 27599. E-mail: jmiller@ocme.unc.edu.
(ARCOS), an automated, comprehensive drug-reporting system that monitors the flow of DEA controlled substances from their point of manufacture to their dispensing/retail level (1) . Trends in medical use and abuse include the simultaneous use of multiple opioids. With the rapid onset of prescription opioid abuse (e.g., oxycodone and hydrocodone) and the need to streamline laboratory procedures, a single method was adopted at the North Carolina Office of the Chief Medical Examiner's (NC-OCME) toxicology laboratory to detect and quantitate all major [codeine, morphine, 6-acetylmorphine (6-AM)] and ketoopioids (hydrocodone, hydromorphone, oxycodone, oxymorphone) in blood and non-urine specimens. This method replaces three separate analytical procedures previously used by this laboratory. Several derivatizing reagents have been utilized for gas chromatography-mass spectrometry (GC-MS) analysis of common morphinian opioids, but disadvantages can be encountered. Problems with reagents include (i) instability of derivatives [pentafluoropropionyl (PFPA), acetyl (acetic anhydride) and silyl (TMS) derivatives], (ii) poor chromatography including unsuitable ions and abundances [PFPA derivatives], (iii) formation of multiple derivatives [trifluoroacetic anhydride (TFAA) and PFPA derivatives], (iv) inadequate recovery [TMS derivatives], and (v) interference or co-elution by other opiates due to incomplete derivatization or side reactions [PFPA and acetyl derivatives] (2--4). In the past, laboratories have used multiple methods to quantitate the opioids, choosing the best derivative for a given analyte (4) . In many cases, it is becoming more common to prescribe and abuse more than one opioid concurrently, therefore, multiple extractions of a specimen to detect all opioids present would be required. As limited specimen volume is routinely encountered, this could be problematic for postmortem laboratories.
Several groups have investigated the use of oxime-TMS derivatization to detect codeine, morphine, and keto analytes in urine by GC-MS analysis (5-7). These studies did not monitor for heroin abuse by the inclusion and detection of 6-AM. In addition, when our laboratory employed these methods for postmortem blood and other difficult specimen matrices, matrix interferences led to unacceptable chromatography and low analyte recovery.
This manuscript describes a dual derivative mechanism for improved separation and quantitation of opiates and their keto analogues in blood and other alternative matrices. To minimize interference(s), two distinct steps were included prior to sample extraction. First, specimens were subjected to a methanolic deproteination step to remove unwanted proteins. Next, the samples were derivatized with hydroxylamine to convert the keto moieties to oxime derivatives preventing enolization and production of multiple analyte peaks. Samples were extracted by a solid-phase technique and quantitated by GC-EI-MS.
Experimental

Specimens
This procedure has been applied to most bodily fluids and tissues including blood, serum, bile, tissue homogenates, gastric contents, vitreous fluid, urine, spinal fluid, and decomposition fluid. Generally, a 2-mL, or gram, sample size is employed unless dilutions are required so that the calibration curve encompasses the expected range of unknown specimens. More than 1000 postmortem specimens were analyzed at NC-OCME spanning a two-year period. Standards and quality control specimens were prepared from expired, banked blood from the American Red Cross that was verified to be negative for opioid analytes.
Materials
Morphine, codeine, hydrocodone, hydromorphone, oxycodone, oxymorphone, 6-AM, and corresponding deuterated analogues were purchased from Cerilliant Corp. (Austin, TX). United Chemical Technologies (Bristol, PA) supplied 200 mg Clean Screen (CSDAU206) solid-phase extraction (SPE) columns. Bis-(trimethylsilyl)-trifluoroacetamide (BSTFA) with 1% trimethylchlorosilane (TMCS) was purchased from Pierce Chemicals (Rockford, IL), and hydroxylamine hydrochloride (NH~OH) was obtained from Fisher Scientific (Pittsburgh, PA). All other chemicals and solvents were ACS or HPLC grade.
Instrumentation
The GC-MS system was composed of an Agilent 6890 GC (Palo Alto, CA), a 5973 mass selective detector (MSD), and a 7683 liquid autosampler. The GC-MS was fitted with a Restek (Bellefonte, PA) base deactivated guard column (5 m x 0.25-ram i.d.) and an HP-]MS capillary column (30 m x 0.25-ram i.d., 0.25-pro film thickness) or equivalent. Co-elution of analytes has been observed with other stationary phases, hence, this column was determined to be most efficient. A 14-min run time occurred after a 1-pL splitless injection into a 250~ injection port equipped with a 0.4-mm single gooseneck liner with base-deactivated fused-silica wool. Oven temperature programming began at 160~ ramping at three intervals: 35~
to 195~ 5~ to 240~ and 30~ to a final temperature of 300~ holding for 2 rain. Helium was used as the carrier gas at a linear velocity of 62 cm/s; flows included a septum purge of 15.0 mL/min at 2.0 rain, and a constant column flow of 2.6 mL/min. The MSD was operated in selective ion mode (SIM) with a transferline temperature of 280~ A 15-or 20-ms dwell time was employed, depending on the number of analytes in the ion monitoring group.
Procedures
Standard analytical curves. Analytical curves for codeine, morphine, hydrocodone, hydromorphone, and oxymorphone were set from 50 to 1000 ng/mL, 6-AM ranged from 10 to 500 ng/mL, and oxycodone was 100 to 2000 ng/mL. Deuterated internal standard was added at a concentration of 250 ng/mL with exception of 6-AM, which was set at 125 ng/mL. A quality control specimen was analyzed with a concentration of 500 ng/mL (6-AM at 250 ng/mL).
Sample preparation. Samples were deproteinated by addition of at least 2.5 mL of methanol, vortex mixed, and allowed to sit at room temperature for 10 min. When a specimen totally absorbed the methanol, an additional aliquot of approximately 2 mL of methanol was added and specimen was vortex mixed until it was fluid and homogeneous. Samples were then centrifuged at 2500 x g for 10-12 min. The supernatant was decanted into a clean test tube and evaporated to a volume less than I mL under nitrogen. Each specimen received a 1-2 mL aliquot of 0.1M acetate buffer (pH 4.5) and 0.5 mL of 10% NH2OH before it was capped, vortex mixed, and heated at 60~ for 1 h by dry heat. For the application of"Total" analytes, 2 mL of ~-glucuronidase solution was added and specimens were heated at 60~ for I h by dry heat prior to the hydroxylamine step. Samples were then allowed to cool to room temperature before proceeding to SPE.
SPE. SPE columns were conditioned by the sequential addition of 2 mL of methanol, 2 mL of ultra pure water, and 2 mL of 0.1M acetate buffer (pH 4.5). Samples were then introduced onto the columns and slowly aspirated (gravity flow). Columns were washed with 2 mL of 0.1M acetate buffer, 2 mL of ultrapure water, and 2 mL of hexanes. The columns were dried by full vacuum for 5-10 rain, followed by an additional wash of 2 mL methanol. Columns were allowed to dry for an additional 5-10 min under full vacuum. 
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and no sample pretreatment can lead to poor chromatography and/or misinterpretation of results due to interferants, including other opioids. Specifically, keto analogues of morphine and codeine, including oxy-and hydro-derivatives containing a C-6 substitution of the hydroxyl group for a keto group, are susceptible to tautomerization when solvents donate protons to the keto groups to form enols. When this occurs, single-step derivatization can result in a mixture of mono-and di-derivatives and accurate quantitation is impossible. If the specimens are derivatized with hydroxylamine prior to SPE and further derivatization, the keto moieties are converted to oxime derivatives effectively preventing enolization (6) . Although this dual derivatization is adequate for relatively clean specimens such as urine, postmortem blood specimens, and other difficult matrices can still demonstrate poor chromatography. Pretreatment of these specimens with methanol removes blood proteins and other potential interferents to improve chromatography substantially. By combining deproteination and dual derivatization, all morphinian opioids can be simultaneously analyzed by GC-EI-MS.
Seven opioid compounds and their respective deuterated analogues were successfully extracted and separated utilizing this technique. Table I lists the absolute retention times (RT), ions monitored, and respective SIM ion groups for these opioids and their deuterated analogues. The peak shapes of selected ions are shown in Figure 1 . All selected ion peaks are Gaussianshaped and show baseline resolution. Representative total ion chromatographs for a calibrator and a postmortem central blood specimen are depicted in Figures 2 and 3 . Other opioids have also been successfully extracted and analyzed by this method including levorphanol/dextrorphan, norcodeine, normorphine, and dihydrocodeine.
A five-point calibration curve for each analyte was obtained using a zero calibrator and four additional calibrators. The zero calibrator was forced through the y-intercept and a bestfit linear curve was obtained. Visual observation of the standard curves, in addition to correlation coefficients (r 2) greater than 0.992 demonstrated linearity.
Quantitation of analytes was based upon the ratios of the integrated ion peak areas to the corresponding deuterated standard analogues. Acceptance criteria required ratios to be within _+ 20% of the ratio value of a calibrator of similar concentration. The limit of detection (LOD) was defined as the concentration corresponding to a signal-to-noise ratio of 3. Minimum detectable levels were 0.70 ng/mL for 6-AM; 2.5 ng/mL for morphine and oxycodone; 3.0 ng/mL for hydromorphone; and 3.5 ng/mL for codeine, hydrocodone, and oxymorphone. The limit of quantitation (LOQ) was defined as the concentration corresponding to a signal-to-noise ratio of 10, agreement to within 10% of the target value, and ion ratios with acceptable limits. LOQs were no more than eight times the LOD for a given analyte [5 ng/mL (6-AM) to 20 ng/mL (oxycodone)]. The upper reportable limit of linearity was established at a concentration of 20% above the highest calibrator. Between-run precision for 12 prepared blood quality control standards (250 ng/mL for 6-AM and 500 ng/mL for all other analytes) analyzed over a three-month period yielded coefficients of variance of 2.79% (morphine) to 5.34% (6-AM). LOD, LOQ, codone. Peak identification: 1, codeine-d3; 2, morphine and morphined3; 3, hydrocodone-d3; 4, 6-AM-d3; 5, hydromorphone-d3; 6, oxycodone and oxycodone-d6; and 7, oxymorphone-da. and precision were all deemed acceptable by NC-OCME for this technique following standard guidelines for a postmortem laboratory.
Conclusions
Our laboratory has been using this procedure for more than two years and has found it to be very acceptable for difficult specimens routinely encountered by postmortem toxicology laboratories. This procedure has been implemented in several other forensic laboratories and has been equally robust in each. This optimized dual derivatization procedure to detect opioids in deproteinated blood offers simplicity, time reduction, reproducibility, clean chromatography, and sensitivity.
